Spexis Faces Imminent Delisting from SIX Exchange

Spexis AG, a biopharmaceutical company based in Allschwil, Switzerland, is set to have its shares delisted from the SIX Swiss Exchange. This follows a suspension that began on July 30, 2024, due to the company's failure to publish its audited 2023 financial results and interim results for 2024. According to the SIX Listing Rules, the suspension has now reached a critical three-month mark with no resolution in sight.

The company's CEO, Jeff Wager, acknowledged the delisting as a significant setback, though not unexpected. Despite the looming delisting, Spexis remains focused on resolving its financial issues. The company may appeal the decision, but it is more inclined to pursue options that will allow it to continue operations as a private entity pending discussions with potential investors.